PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (GH), a leading precision oncology company, today announced new real-world data published in Current Medical Research and Opinion finding ...

Living in rural Colorado means long days, hard work, and taking care of the people and land we love. Whether you’re tending crops, working cattle, raising a family, or enjoying retirement, your health ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer screening (CRC) is now covered for active-duty service members and ...

Strategic collaboration to enable streamlined and accelerated access to Shield blood-based colorectal cancer screening test across Quest’s vast network Physicians nationwide now have the ability to ...

Colonoscopy is the gold standard for detecting colon cancer, but every year about 50 million people in the U.S. who qualify for a colonoscopy don't get it done, according to the American Cancer ...

Approval demonstrates unique value of Shield test for CRC screening and improves Medicare pricing The CMS determination confirms that the Shield test meets the criteria for ADLT status, which is ...

Guardant Health, Inc. (NASDAQ:GH) stock is trading higher on Tuesday after the U.S. Food and Drug Administration (FDA) granted Breakthrough Device designation to the company’s Shield multi-cancer ...

Active-duty service members and eligible family members now have access to blood test for colorectal cancer screening with no copay Shield is the first and only blood test approved by the FDA as a ...